文献速递乳腺癌

帕博利珠单抗联合艾立布林治疗HR阳性HER2阴性局部复发或转移性乳腺癌的Ⅱ期研究

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.
PubMed 文献 · Eur J Cancer · 2021-03-29

KELLY是一项开放标签、多中心、单臂Ⅱ期试验,入组44例既往接受过内分泌治疗及1–2线化疗的HR阳性、HER2阴性不可手术局部复发或转移性乳腺癌患者,评估帕博利珠单抗联合艾立布林的疗效与安全性。

要点

  • 该联合方案在经重度治疗的HR阳性HER2阴性转移性乳腺癌中显示抗肿瘤活性

核心结论

  • 帕博利珠单抗联合艾立布林在经重度治疗的HR阳性、HER2阴性局部复发或转移性乳腺癌患者中显示出令人鼓舞的抗肿瘤活性,安全性与耐受性同艾立布林或帕博利珠单抗单药相似。

研究设计与样本

  • 开放标签、多中心、单臂Ⅱ期试验(KELLY,NCT03222856),入组44例年龄≥18岁、HR阳性、HER2阴性、不可手术局部复发或转移性乳腺癌女性患者。
  • 主要终点为临床获益率,安全性与活性分析纳入符合筛选标准并至少接受1剂研究治疗的全部患者。

临床怎么用

  • 对于既往内分泌治疗及1–2线化疗后的HR阳性、HER2阴性局部复发或转移性乳腺癌患者,可考虑帕博利珠单抗联合艾立布林方案。
  • 治疗中需重点监测中性粒细胞减少、贫血、乏力、腹泻及外周神经病变,并警惕免疫相关不良事件。

局限性

  • 本研究为单臂Ⅱ期试验,样本量44例,未设对照组,结果需随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pembrolizumab has modest activity if used in patients with hormone-receptor-positive (HR+), HER2-negative, previously treated metastatic breast cancer (BC). Our study investigated whether there would be any clinical benefit in combining chemotherapy with pembrolizumab in a similar patient population. METHODS: This single-arm, phase Ⅱ trial enrolled women aged ≥18 years with HR+, HER2-negative, inoperable, locally recurrent or metastatic BC. Patients were previously treated with hormonal therapy and 1-2 chemotherapy regimens for locally recurrent and/or metastatic BC. On each 21-day cycle, patients received intravenous pembrolizumab 200 mg on day 1 and eribulin 1∙23 mg/m2 on days 1 and 8. The primary endpoint was the clinical benefit rate. Analysis of safety and activity was carried out in all patients who met the screening criteria and received at least 1 dose of study treatment. The trial is registered at ClinicalTrials.gov, NCT03222856. RESULTS: Of the 44 patients enrolled between January 29 and October 17, 2018, clinical benefit was achieved in 25 (56∙8%, 95% confidence interval [CI]: 41∙0-71∙7), objective response in 18 (40∙9%, 95% CI: 26∙3-56∙8), median progression-free survival was 6∙0 months (95% CI: 3∙7-8∙4), and 1-year overall survival was 59∙1% (95% CI: 45∙8-76∙2). The most common treatment-emergent adverse events (AEs) of any grade were neutropenia (20 [45∙5%]), anaemia (17 [38∙6%]), alopecia (19 [43∙2%]), asthenia (19 [43∙2%]), diarrhoea (14 [31∙8%]), fatigue (14 [31∙8%]), and peripheral neuropathy (12 [27∙3%]). Serious AEs occurred in 14 (31∙8%) patients including febrile neutropenia (3 [6∙8%]), neutropenia (2 [4∙5%]), fever (2 [4∙5%]) and peripheral neuropathy (2 [4∙5%]). Immune-related AEs occurred in 11 (25∙0%) patients. One (2∙3%) patient died of cardiac arrest unrelated to study treatment. CONCLUSION: Pembrolizumab plus eribulin demonstrates encouraging antitumour activity in patients with heavily pre-treated, HR+, HER2-negative, locally recurrent or metastatic BC. The safety and tolerability of the combination is similar to eribulin or pembrolizumab monotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pérez-García JM, Llombart-Cussac A, G Cortés M, et al. Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial. Eur J Cancer. 2021. PMID: 33794440. doi:10.1016/j.ejca.2021.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。